前言：目的实现单剂量个体化给药，确保用药安全。
OBJECTIVE: to realize individualized medication and to ensure medication safety.
同时选择适当的药物作为探针来评价CYP的活性，为实现临床个体化给药提供科学依据。
Moreover, suitable drug can be selected to evaluate the action of CYP, and it can offer the scientific assurance for clinical individual therapy.
结论：治疗药物监测结果需结合患者病情与临床疗效综合判断，方能实现个体化给药这一目的。
Conclusion: Individualized medication can only be achieved on account of an overall judgment involving therapeutic drug monitoring results, patient conditions and clinical efficacy.
结论每一个低分子肝素产品间都存在着明显的差异，具有不同的特点，临床使用中应按指征个体化给药。
CONCLUSION Every low molecule heparin product has its own feature, and they should be used individualized in clinic.
目的：寻找丙戊酸药物浓度与CYP2C19基因多态性的关系，以便临床根据患者的基因型进行个体化给药。
OBJECTIVE To investigate the association between valproic acid (VAP) plasma concentration at steady state (Css) and CYP2C19 gene polymorphisms for better individualized medication.
目的：通过对90例氨茶碱血药浓度监测结果的分析，提出个体化给药建议，使氨茶碱在临床上使用更安全有效。
Objective: To put forward individual dose proposal by the analysis on blood drug concentration of Aminophylline of 90 cases for its safe and efficient clinical usage.
结果：338例用药存在不同程度的问题，主要表现在联合用药、药物配伍、抗生素应用、个体化给药与治疗药物监测方面。
Results: The problems of drug use were presented, such as improper drug combinations, drug incompatibility, irrational use of antibiotics and low level of drug monitoring.
结论老年心衰病人的个体药代动力学参数波动范围大，个体差异更为突出，临床应在血药浓度监测的基础上实行最佳个体化给药。
Conclusions there is a significant individual variation in the pharmacokinetic parameters, therefore, the dose should be individualized on the basis of blood drug concentration monitoring.
本文经静脉注射测定了病人心律平药动学参数，并对口服心律平的给药方案个体化进行了研究。
The pharmacokinetic parameter of patients' propafenone was measured by intravenous injection and the dosage regimen individualization by oral administration was studied.
本文经静脉注射测定了病人心律平药动学参数，并对口服心律平的给药方案个体化进行了研究。
The pharmacokinetic parameter of patients' propafenone was measured by intravenous injection and the dosage regimen individualization by oral administration was studied.
应用推荐